Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.
about
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosingCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigmMercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fictionChildhood Acute Lymphoblastic Leukemia: Progress Through CollaborationOutcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trialIncidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology.Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients.Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia.Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine modelClinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries.Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment responseBioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.Childhood B-acute lymphoblastic leukemia: a genetic update.Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative data.DNA methylation analysis of bone marrow cells at diagnosis of acute lymphoblastic leukemia and at remission.Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children.Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.Improved prognosis for older adolescents with acute lymphoblastic leukemia.Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemiaThe mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing.Epidemiology of therapy-related myeloid neoplasms after treatment for pediatric acute lymphoblastic leukemia in the nordic countries.Accurate detection of subclonal single nucleotide variants in whole genome amplified and pooled cancer samples using HaloPlex target enrichment.Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia.Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance.Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2AMethotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.Outcomes after induction failure in childhood acute lymphoblastic leukemia.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemiaRelapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia
P2860
Q24632749-BEF18602-CEBB-4B07-BFE7-834CD00AE2D5Q26859144-403F4D42-52DB-403C-8386-AD9D1DFF82F0Q26866379-B6F6338A-BC7F-4A0B-96A7-DF02FDF77294Q27023839-5CA2C237-166A-4655-B888-A9D5C1B119AFQ28087637-7C728C5B-3B98-4DAE-9155-EBCBBD2C5ABBQ28543517-92134319-FD10-42B5-8D1D-AC2DC58BDBC8Q30631947-60AF3906-EECD-4D12-A10A-FFDA50A8769EQ31170949-4189D899-91C6-4AA1-B7AF-39541F53E873Q33421300-C01BFE5B-4724-4ABF-BA4F-F7F87C208506Q33585130-E7A6CD59-BE8C-4B79-9CD8-49AA87E97F4BQ33603164-0F0332DB-E326-4BCE-AFB9-42AC878DAFDEQ33615910-332DA28A-69F1-4046-B6FF-62816F4AB023Q33674158-63674241-293F-49EA-8349-ECBCA5019167Q33729728-FF0BE341-2FA0-42C6-876A-11C5DF3085D2Q33777616-E98CEB0F-BDD4-4E25-8F57-888D83EA8468Q33998291-F0DC52A6-0986-4F14-99AB-F190973A6B0AQ34192080-AEA74940-08A3-43F0-A437-2A1E0C76F90BQ34228412-4B81AF4B-F030-4AE2-971F-889EC3B90E0EQ34411660-D767AA57-15E0-41EB-9FC7-EDD834A8FE28Q34482019-E67B99E4-9F93-48A2-92A2-A69FC29FA65CQ34488796-A79A6BA0-BD8A-4AA1-8B6A-083A14CBE747Q34679298-26A18177-9A14-4D40-9169-AD842BEE4874Q34707213-409973FD-8977-4676-B5C2-10C510EF34DBQ34764504-42EE1D9E-C695-4D01-8CB8-605C35FE2EF9Q34769855-AABD4231-DB5C-49BD-B7D3-7CF41F61FF22Q35023231-0CB7304A-1E23-43A2-8769-6991EDADA9C5Q35040001-88E5A498-1D33-4D29-84F1-B7A9848C3F81Q35061962-0A582948-B7BC-46A4-8342-C7E519F84731Q35112206-777C7FA1-34C7-4F9F-9CD3-0B01658DAE1CQ35129383-DDF88E7A-A5A9-44EA-9B4A-2CA67D509B88Q35206306-EDE2B295-8361-4202-A2AE-FB8F910941ECQ35545539-8439BBB8-FFFC-4E29-A4C6-992A412D5429Q35684384-D5EA017D-4DF0-4899-81ED-43717C48BF07Q35976588-762B068F-7757-461E-8F9C-3C8546921F9AQ36029619-AA50B128-4F3B-4C95-A67A-000AE25EA625Q36163029-8A6D909E-FC68-4CF5-BC72-0FF319925DC3Q36213239-C9C979DB-DBA2-4F06-9EAF-53DEABA16AD8Q36420748-7A8142AF-6583-4939-B8C9-19B93BDA13A1Q36547791-1529B433-DC10-4CEC-87AE-6892B9781C58Q36605135-65E38A8C-AAB2-4E86-9608-BDB903AA2FDF
P2860
Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.
@en
Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.
@nl
type
label
Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.
@en
Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.
@nl
prefLabel
Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.
@en
Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P356
P1433
P1476
Long-term results of NOPHO ALL ...... acute lymphoblastic leukemia.
@en
P2093
E Forestier
J Kristinsson
M Hellebostad
M Taskinen
Nordic Society of Paediatric Haematology and Oncology
S Söderhäll
P2860
P2888
P304
P356
10.1038/LEU.2009.251
P577
2009-12-10T00:00:00Z
P6179
1034618149